At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
Elotuzumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
In Brief
A Phase 2 clinical trial evaluating Elotuzumab, Pomalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 117 participants across 55 sites in 11 countries.
Detailed Summary
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United States
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionJan 2018
Study CompletionOct 2021
TodayJul 2026
First PostedJan 13, 2016
Enrollment StartMar 18, 2016
Primary CompletionJan 17, 2018
Study CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.5 years ago
Interventions
Elotuzumabdrug
Pomalidomidedrug
Dexamethasonedrug